Paul Schimmel
InvestorFounderProfessor of Biochemistry and Biophysics at MIT at Cardinal Partners · Non-Management Director at aTYR PHARMA
FoundedaTYR PHARMA
About
Paul Schimmel is the Ernest and Jean Hahn Professor of Cell and Molecular Biology at The Scripps Research Institute, with campuses in Florida and California. He earned his PhD in biochemistry and biophysics from MIT in 1966 and previously held the John D. and Catherine T. MacArthur Professorship in MIT's Department of Biology. He has authored roughly 500 scientific papers and a three-volume textbook on biophysical chemistry, holds numerous patents, and has cofounded or served as founding director of several biotechnology companies, seven of which became NASDAQ-listed.
Invests in
Biotech
Non-Management Director at aTYR PHARMA
Intro paths
In turn, Paul can intro founders to aTYR PHARMA's investors below.
Deals · 1
aTYR PHARMABoard seat
via Cardinal Partners · filed Sep 2017 · $45.8M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Cardinal Partners
Frequently asked questions
- Who is Paul Schimmel?
- Paul Schimmel is the Ernest and Jean Hahn Professor of Cell and Molecular Biology at The Scripps Research Institute, with campuses in Florida and California. He earned his PhD in biochemistry and biophysics from MIT in 1966 and previously held the John D. and Catherine T. MacArthur Professorship in MIT's Department of Biology. He has authored roughly 500 scientific papers and a three-volume textbook on biophysical chemistry, holds numerous patents, and has cofounded or served as founding director of several biotechnology companies, seven of which became NASDAQ-listed.
- Where does Paul Schimmel work?
- Paul Schimmel is Non-Management Director of aTYR PHARMA and Professor of Biochemistry and Biophysics at MIT at Cardinal Partners.
- What does Paul Schimmel invest in?
- Paul Schimmel invests in Biotech.
- What companies did Paul Schimmel found?
- Paul Schimmel founded aTYR PHARMA.
- What boards does Paul Schimmel sit on?
- Paul Schimmel holds tracked board seats at aTYR PHARMA.